US News Pulse Newsroom
Editorial Team
Published : Nov 21, 2026
Online Edition

CTE Blood Test Could Detect Brain Disease in Living Patients, JAMA Studies Find

CTE Blood Test Could Detect Brain Disease in Living Patients, JAMA Studies Find

For the first time, doctors may be able to diagnose chronic traumatic encephalopathy — CTE — in a living person with a simple blood test. Two studies published in the Journal of the American Medical Association report that a protein marker in the blood, eMTBR-tau, was far higher in people with advanced CTE than in people with little or no sign of the disease. Until now, CTE could only be confirmed by examining the brain after death.

The findings, reported on November 19, 2026, could transform care, research and trials — though both teams stress the test is not ready for clinics yet.

Key Points

  • Two studies published in JAMA show a blood test may detect CTE in living people for the first time — today the disease can only be confirmed by examining the brain after death.
  • A Boston University and Banner Health team studied 21 former football players and found blood levels of eMTBR-tau significantly higher in high-stage CTE than in low-stage or no CTE.
  • A Washington University study of 229 participants found the related marker eMTBR-tau243 elevated in advanced CTE and rising with disease severity.
  • Of the 21 football players in the Boston study, 18 had CTE, 16 of them high-stage — McKee stage 3 or 4.
  • Researchers say a commercial test could be available within five years, but both studies are small and preliminary and need validation before clinical use.

What Happened

Two research teams working independently reached the same conclusion: a blood marker can separate people with advanced CTE from people without it. The first team, from Boston University and Banner Health, studied 21 former American football players — 12 professional, seven college and two high school players — whose blood was drawn in life and whose brains were donated for examination after death. Eighteen had CTE, and 16 had high-stage disease, McKee stage 3 or 4. In those players, blood levels of eMTBR-tau were significantly higher than in players with low-stage CTE or no CTE.

The Washington University team studied 229 participants and found the related marker eMTBR-tau243 elevated in advanced CTE, rising with disease severity — the first consistent evidence that a blood test can track a disease invisible in life.

Background: A Disease That Could Only Be Diagnosed After Death

CTE is a degenerative brain disease linked to repeated head impacts, most famously in American football, but also in other contact sports and in military service. It is associated with memory loss, confusion, mood changes, depression and, in later stages, dementia. The disease is driven by the build-up of an abnormal form of the tau protein in the brain.

For families and for medicine, the cruelest feature of CTE has been its invisibility. A player could suffer for years with symptoms that looked like depression, early dementia or simply ageing, and no scan or test could say whether CTE was the cause. Confirmation came only at autopsy — so patients never got a certain diagnosis, doctors could never tailor treatment, and researchers could never be sure the people in their trials actually had CTE.

The search for a living test has run for years, through brain scans, spinal fluid and blood markers, with no result reliable enough for the clinic. The new studies focus on a fragment of tau itself — eMTBR-tau — that appears in the blood when the disease is advanced.

How the CTE Blood Test Works

The test measures eMTBR-tau, a fragment of the tau protein, in a blood sample. In the Boston study, the marker was significantly higher in former players whose brains later showed high-stage CTE than in those with low-stage disease or none. The Washington study found the same pattern with eMTBR-tau243: levels were elevated in advanced CTE and climbed as the disease grew more severe.

That dose-response pattern — the worse the disease, the higher the marker — is what makes researchers hopeful. A marker that tracks severity could follow the disease over time and judge whether a treatment is working. But the test compares blood from living people against brain findings after death, so larger studies are needed before any clinic can offer it.

Reactions

The researchers behind both studies describe the results as a breakthrough with limits. A commercial test could be available within five years, they say, but both studies are small and preliminary and need validation before clinical use. The Boston study followed only 21 former players, and the Washington study, at 229 participants, still needs repeating in bigger and more diverse groups.

That caution matters because a test for CTE would carry heavy consequences: a positive result could shape medical care, decisions about work and sport, and family planning. The marker also performed best in high-stage disease; whether it can catch CTE early, when treatment would matter most, is still open.

Why It Matters

A reliable blood test would change the disease three ways at once. It would give patients and families an answer while there is still time to act. It would give doctors a way to distinguish CTE from conditions with similar symptoms, such as Alzheimer's disease or depression, which need very different treatment. And it would let researchers run proper clinical trials, enrolling people known to have CTE and measuring whether a drug slows it.

The stakes reach beyond football: CTE has been found in military veterans exposed to blasts, in boxers, ice hockey and rugby players, and in others with repeated head trauma. A blood test would let all of them be studied and, eventually, treated on evidence rather than guesswork.

What Happens Next

The next step is validation: larger studies in more people, including women, non-athletes and people at earlier stages, to confirm the marker holds up outside the two original groups. If those succeed, the test would still need regulatory clearance — the researchers' estimate of a commercial test within five years reflects that path.

For anyone worried about CTE today, the advice has not changed: the test is not available, and no clinic can order it yet. People with symptoms after repeated head impacts should talk to their doctor. For readers following brain research, our earlier coverage includes a CAR-T therapy that wiped out deadly childhood brain tumours in every mouse tested and the obituary of Marsha Linehan, creator of dialectical behavior therapy.

Frequently Asked Questions

What is CTE?
Chronic traumatic encephalopathy is a degenerative brain disease linked to repeated head impacts, associated with memory loss, mood changes and dementia, driven by abnormal tau protein in the brain.

How is CTE diagnosed today?
Only after death, by examining donated brain tissue. No scan or blood test can diagnose it in a living person.

What did the two new JAMA studies find?
That blood marker eMTBR-tau was significantly higher in high-stage CTE, and eMTBR-tau243 rose with disease severity — the first evidence a blood test can detect CTE in life.

When will the blood test be available?
Researchers say a commercial test could be available within five years, but both studies are small and preliminary and need validation and clearance first.

Who was studied?
Boston University and Banner Health studied 21 former American football players; Washington University studied 229 participants.

US News Pulse
Written by
US News Pulse Newsroom
Editorial Team

The US News Pulse newsroom covers breaking news across the United States and the world, working from wire services, official statements and on-the-record sources. Every story is reviewed against our editorial standards before publication. Corrections and tips: info@usnewspulse.com

About our newsroom

Leave a Comment

  • Latest
  • Popular

Mike Pence Blames Trump Iran Campaign Halt for Republican Mi

1

Kushner impulsa diálogo directo Europa-Rusia y cinco países

2

Avión de combate de EE. UU. derribado en Irán: un tripulante

3

Former Boxing Champion Jorge Linares Detained by ICE in El P

4

Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion in Rare

5

Irán afirma que sus drones golpearon defensas Patriot de EE.

6

United Airlines prohíbe a los agentes de IA reservar vuelos

7

United Airlines Outage Delays 554 Flights Days After FAA Gro

8

Bitcoin Crashes Below $70,000 for First Time Since August, F

9

Trump Media Faces $1 Billion Cash Demand on November 30 as S

10

FISA Section 702 Renewal: Trump's Spy Chiefs Press Congress

11

Amenaza de misil hutí alcanza Riad y deja daños materiales,

12

Quinnipiac University Lockdown Ends After Five-Hour Police S

13

Trail Blazers Beat Bucks 124-114 as Lillard Scores 33 in Mil

14

Lauren Boebert empaca en una furgoneta y dice que Trump 'per

15

Zverev and Shelton Win ATP Finals Openers in Turin as Season

16

Trump Blasts Judge's Golf Course Halt as 'Highly Destructive

17

Las ventas minoristas en EE. UU. suben 0,2% en octubre hasta

18

Tax Records Name Heather Booth Behind Democrats' Midterm Mes

19

Los Blues vencen 5-2 a los Penguins en Pittsburgh con dos go

20